Invitae releases environmental, social and governance (ESG) report

Report details the company’s commitment to improving healthcare through the power of genetic information and reveals fiscal 2023 environmental, social and governance initiatives

san francisco, April 22, 2024 /PRNewswire/—— invite The leading medical genetics company (OTC: NVTA ) today released its 2024 Environmental, Social and Governance (ESG) Report. The report provides a comprehensive introduction to the company’s ESG approach, its performance and progress in fiscal year 2023 through measurable data and indicators.

“At Invitae, sustainability is more than just a function; it is woven into the fabric of our DNA. We have used sustainability and ESG as catalysts for change,” said Eric Kaiser, Chief Sustainability Officer at Invitae. “Throughout our journey, our unwavering commitment to our patients and customers remains critical, ensuring our actions have a positive impact on healthcare, the environment and society.”

The report provides an in-depth review of progress made on company-wide ESG measures over the past year. The company’s notable achievements include:

• Expanding patient access and partnerships: We are focused on expanding access to genetic testing, developing policies, programs and guidelines to make more patients and their families eligible for testing. Since our founding, we have proudly served more than 4.6 million patients and in 2023 expanded our partnerships in rare diseases and data to advance drug discovery.
• Advancing genetic insights: We have enhanced our industry-leading variant classification and invitation generation capabilities through cutting-edge technologies such as machine learning and functional modeling. Since 2020, we have seen a 40% reduction in uncertainty rates for Invitae Generation technology. These tools allow us to continue to improve the accuracy of genetic insights.
• quality standards: We have obtained market authorization USA The recognition of one of our hereditary germline cancer panels by the (U.S.) Food and Drug Administration (FDA) demonstrates our rigorous standards and product quality. Our hereditary cancer team provides patients and their families with important information to make informed medical decisions.
• environmental sustainability: We have made progress in managing Scope 1 and Scope 2 greenhouse gas emissions and assessed the relevance of different Scope 3 categories in the value chain. We have also adopted an environmental policy at board level. Environmental sustainability is at the core of our ESG journey.

“I sincerely thank our outstanding team members for their dedication, hard work and focus on patients, as well as our greater mission of bringing genetic information into mainstream medicine and creating a healthier future for all,” he said. Ken Knight, President and CEO of Invitae. “I hope you will join me in accessing better health care through genetic testing and creating a brighter future for the well-being of our planet and our people. Together, we will continue to have a profound impact on health care and the world around us. Impact.

Invitae’s full 2024 ESG report is available for download here.

About Invitai
Invitae (OTC: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to leverage digital technology to deliver timely genetic information. Our goal is to provide accurate and actionable answers to enhance medical decision-making for individuals and their families. Invitae’s genetics experts take a rigorous approach to data and research that is fundamental to their mission of bringing comprehensive genetic information into mainstream medicine to improve health care for billions of people.

To learn more, please visit invitation network and follow updates LinkedIn, X, Instagramand Facebook @invite.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s ESG and sustainability plans and initiatives and their expected impact. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be relied upon as indicative of future performance.These risks and uncertainties include, but are not limited to: risks and uncertainties related to the Company’s ability to successfully complete its reorganization plan under Chapter 11; the Company’s ability to continue normal operations while the Chapter 11 proceedings are pending; Chapter 11 Potential adverse effects of the Chapter proceedings on the Company’s business, financial condition, liquidity and operating performance; The Company’s ability to use rapidly changing genetic data to accurately and consistently interpret test results; Risks related to litigation; Security breaches, loss of data and other disruption; laws and regulations applicable to the Company’s business; and other risks set forth in the Company’s filings with the Securities and Exchange Commission, including those set forth in the Company’s quarterly reports on Form 10-Q for the quarter ended September 30, 2023. These forward-looking statements speak only as of the date of this press release, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

Invite PR contact:
Amy Sands Hudsock
[email protected]

SOURCE Invitae Corporation